A novel approach to drug development in heart failure: Towards personalized medicine

Canadian Journal of Cardiology

Volumn 30, Issue 3, 2014, Pages 288-295

  Liu, Licette C Y ^a   Voors, Adriaan A ^a   Valente, Mattia A E ^a   Van der Meer, Peter ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR AGENTS; DISEASE MANAGEMENT; HEART FAILURE; HUMANS; INDIVIDUALIZED MEDICINE;

EID: 84894322433     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2013.12.005     Document Type: Review

References (84)

1. McMurray J.J., Adamopoulos S., Anker S.D., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012, 14:803-869.
2. Wong C.Y., Chaudhry S.I., Desai M.M., et al. Trends in comorbidity, disability, and polypharmacy in heart failure. Am J Med 2011, 124:136-143.
3. Zhou H.H., Koshakji R.P., Silberstein D.J., et al. Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites. NEngl J Med 1989, 320:565-570.
4. Exner D.V., Dries D.L., Domanski M.J., et al. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. NEngl J Med 2001, 344:1351-1357.
5. Carson P., Ziesche S., Johnson G., et al. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. JCard Fail 1999, 5:178-187.
6. Rathore S.S., Wang Y., Krumholz H.M. Sex-based differences in the effect of digoxin for the treatment of heart failure. NEngl J Med 2002, 347:1403-1411.
7. Felker G.M., Benza R.L., Chandler A.B., et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. JAm Coll Cardiol 2003, 41:997-1003.
8. Cleland J.G., Tendera M., Adamus J., et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006, 27:2338-2345.
9. Massie B.M., Carson P.E., McMurray J.J., et al. Irbesartan in patients with heart failure and preserved ejection fraction. NEngl J Med 2008, 359:2456-2467.
10. Yusuf S., Pfeffer M.A., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003, 362:777-781.
11. Nieminen M.S., Harjola V.P., Hochadel M., et al. Gender related differences in patients presenting with acute heart failure. Results from EuroHeart Failure Survey II. Eur J Heart Fail 2008, 10:140-148.
12. Pina I.L., Kokkinos P., Kao A., et al. Baseline differences in the HF-ACTION trial by sex. Am Heart J 2009, 158(suppl 4):S16-S23.
13. Meyer S., van der Meer P., van Deursen V.M., et al. Neurohormonal and clinical sex differences in heart failure. Eur Heart J 2013, 34:2538-2547.
14. Ghali J.K., Krause-Steinrauf H.J., Adams K.F., et al. Gender differences in advanced heart failure: insights from the BEST study. JAm Coll Cardiol 2003, 42:2128-2134.
15. Meyer S., van der Meer P., Massie B.M., et al. Sex-specific acute heart failure phenotypes and outcomes from PROTECT. Eur J Heart Fail 2013, 15:1374-1381.
16. Murphy E. Estrogen signaling and cardiovascular disease. Circ Res 2011, 109:687-696.
17. Follath F., Cleland J.G., Klein W., et al. Etiology and response to drug treatment in heart failure. JAm Coll Cardiol 1998, 32:1167-1172.
18. Sliwa K., Blauwet L., Tibazarwa K., et al. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. Circulation 2010, 121:1465-1473.
19. Murphy C.J., Oudit G.Y. Iron-overload cardiomyopathy: pathophysiology, diagnosis, and treatment. JCard Fail 2010, 16:888-900.
20. Huang D., Cheng J.W. Pharmacologic management of heart failure with preserved ejection fraction. Ann Pharmacother 2010, 44:1933-1945.
21. Joglar J.A., Acusta A.P., Shusterman N.H., et al. Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction: retrospective analysis of the US Carvedilol Heart Failure Trials Program. Am Heart J 2001, 142:498-501.
22. van Veldhuisen D.J., Aass H., El Allaf D., et al. Presence and development of atrial fibrillation in chronic heart failure. Experiences from the MERIT-HF Study. Eur J Heart Fail 2006, 8:539-546.
23. Lechat P., Hulot J.S., Escolano S., et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation 2001, 103:1428-1433.
24. Mulder B.A., van Veldhuisen D.J., Crijns H.J., et al. Effect of nebivolol on outcome in elderly patients with heart failure and atrial fibrillation: insights from SENIORS. Eur J Heart Fail 2012, 14:1171-1178.
25. Rienstra M., Damman K., Mulder B.A., et al. Beta-blockers and outcome in heart failure and atrial fibrillation. a meta-analysis. JACC: Heart Failure 2013, 1:21-28.
26. Lander E.S., Linton L.M., Birren B., et al. Initial sequencing and analysis of the human genome. Nature 2001, 409:860-921.
27. Venter J.C., Adams M.D., Myers E.W., et al. The sequence of the human genome. Science 2001, 291:1304-1351.
28. Collins F.S., Green E.D., Guttmacher A.E., et al. Avision for the future of genomics research. Nature 2003, 422:835-847.
29. Hershberger R.E., Morales A., Siegfried J.D. Clinical and genetic issues in dilated cardiomyopathy: a review for genetics professionals. Genet Med 2010, 12:655-667.
30. Alcalai R., Seidman J.G., Seidman C.E. Genetic basis of hypertrophic cardiomyopathy: from bench to the clinics. JCardiovasc Electrophysiol 2008, 19:104-110.
31. Fang K.C. Clinical utilities of peripheral blood gene expression profiling in the management of cardiac transplant patients. JImmunotoxicol 2007, 4:209-217.
32. Srivastava P.K., Duan F. Harnessing the antigenic fingerprint of each individual cancer for immunotherapy of human cancer: genomics shows a new way and its challenges. Cancer Immunol Immunother 2013, 62:967-974.
33. Simon R., Roychowdhury S. Implementing personalized cancer genomics in clinical trials. Nat Rev Drug Discov 2013, 12:358-369.
34. Borjesson M., Magnusson Y., Hjalmarson A., et al. Anovel polymorphism in the gene coding for the beta(1)-adrenergic receptor associated with survival in patients with heart failure. Eur Heart J 2000, 21:1853-1858.
35. Magnusson Y., Levin M.C., Eggertsen R., et al. Ser49Gly of beta1-adrenergic receptor is associated with effective beta-blocker dose in dilated cardiomyopathy. Clin Pharmacol Ther 2005, 78:221-231.
36. Levin M.C., Marullo S., Muntaner O., et al. The myocardium-protective Gly-49 variant of the beta 1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation. JBiol Chem 2002, 277:30429-30435.
37. Troncoso R., Moraga F., Chiong M., et al. Gln(27)Glubeta(2)-adrenergic receptor polymorphism in heart failure patients: differential clinical and oxidative response to carvedilol. Basic Clin Pharmacol Toxicol 2009, 104:374-378.
38. Kaye D.M., Smirk B., Williams C., et al. Beta-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure. Pharmacogenetics 2003, 13:379-382.
39. Green S.A., Turki J., Innis M., et al. Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 1994, 33:9414-9419.
40. Littlejohn M.D., Palmer B.R., Richards A.M., et al. Ile164 variant of beta2-adrenoceptor does not influence outcome in heart failure but may interact with beta blocker treatment. Eur J Heart Fail 2008, 10:55-59.
41. Lobmeyer M.T., Gong Y., Terra S.G., et al. Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure. Pharmacogenet Genomics 2007, 17:277-282.
42. Hein L., Altman J.D., Kobilka B.K. Two functionally distinct alpha2-adrenergic receptors regulate sympathetic neurotransmission. Nature 1999, 402:181-184.
43. Rigat B., Hubert C., Alhenc-Gelas F., et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. JClin Invest 1990, 86:1343-1346.
44. Raynolds M.V., Bristow M.R., Bush E.W., et al. Angiotensin-converting enzyme DD genotype in patients with ischaemic or idiopathic dilated cardiomyopathy. Lancet 1993, 342:1073-1075.
45. Andersson B., Sylven C. The DD genotype of the angiotensin-converting enzyme gene is associated with increased mortality in idiopathic heart failure. JAm Coll Cardiol 1996, 28:162-167.
46. McNamara D.M., Holubkov R., Postava L., et al. Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. JAm Coll Cardiol 2004, 44:2019-2026.
47. Han B., Hasin Y. Cardiovascular effects of natriuretic peptides and their interrelation with endothelin-1. Cardiovasc Drugs Ther 2003, 17:41-52.
48. Atrial of the beta-blocker bucindolol in patients with advanced chronic heart failure. NEngl J Med 2001, 344:1659-1667. Beta-Blocker Evaluation of Survival Trial Investigators.
49. Taylor M.R., Slavov D., Humphrey K., et al. Pharmacogenetic effect of an endothelin-1 haplotype on response to bucindolol therapy in chronic heart failure. Pharmacogenet Genomics 2009, 19:35-43.
50. Swain S.M., Whaley F.S., Ewer M.S. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003, 97:2869-2879.
51. Colombo A., Meroni C.A., Cipolla C.M., et al. Managing cardiotoxicity of chemotherapy. Curr Treat Options Cardiovasc Med 2013, 15:410-424.
52. Wojnowski L., Kulle B., Schirmer M., et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 2005, 112:3754-3762.
53. Lemieux J., Diorio C., Cote M.A., et al. Alcohol and HER2 polymorphisms as risk factor for cardiotoxicity in breast cancer treated with trastuzumab. Anticancer Res 2013, 33:2569-2576.
54. Visscher H., Ross C.J., Rassekh S.R., et al. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. JClin Oncol 2012, 30:1422-1428.
55. Schmitter D, Cotter G, Voors AA. Clinical use of novel biomarkers in heart failure: towards personalized medicine. Heart Fail Rev 2013 [Epub ahead of print].
56. Preston R.A., Materson B.J., Reda D.J., et al. Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. JAMA 1998, 280:1168-1172.
57. Lim P.O., MacFadyen R.J., Struthers A.D. Is there a role for renin profiling in selecting chronic heart failure patients for ACE inhibitor treatment?. Heart 2000, 83:257-261.
58. Weir M.R., Saunders E. Renin status does not predict the anti-hypertensive response to angiotensin-converting enzyme inhibition in African-Americans. Trandolapril Multicenter Study Group. JHum Hypertens 1998, 12:189-194.
59. Konstam M.A., Gheorghiade M., Burnett J.C., et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007, 297:1319-1331.
60. Lanfear D.E., Sabbah H.N., Goldsmith S.R., et al. Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. Circ Heart Fail 2013, 6:47-52.
61. Morawiec B., Kawecki D. Copeptin: a new marker in cardiology. JCardiovasc Med (Hagerstown) 2013, 14:19-25.
62. Zannad F., Alla F., Dousset B., et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 2000, 102:2700-2706.
63. Jourdain P., Jondeau G., Funck F., et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. JAm Coll Cardiol 2007, 49:1733-1739.
64. Berger R., Moertl D., Peter S., et al. N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study. JAm Coll Cardiol 2010, 55:645-653.
65. Januzzi J.L., Rehman S.U., Mohammed A.A., et al. Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. JAm Coll Cardiol 2011, 58:1881-1889.
66. Troughton R.W., Frampton C.M., Yandle T.G., et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000, 355:1126-1130.
67. Pfisterer M., Buser P., Rickli H., et al. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA 2009, 301:383-392.
68. Lainchbury J.G., Troughton R.W., Strangman K.M., et al. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. JAm Coll Cardiol 2009, 55:53-60.
69. Persson H., Erntell H., Eriksson B., et al. Improved pharmacological therapy of chronic heart failure in primary care: a randomized Study ofNT-proBNP Guided Management of Heart Failure-SIGNAL-HF (Swedish Intervention study-Guidelines and NT-proBNP AnaLysis in Heart Failure). Eur J Heart Fail 2010, 12:1300-1308.
70. Eurlings L.W., van Pol P.E., Kok W.E., et al. Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. JAm Coll Cardiol 2010, 56:2090-2100.
71. Shah M.R., Califf R.M., Nohria A., et al. The STARBRITE trial: a randomized, pilot study of B-type natriuretic peptide-guided therapy in patients with advanced heart failure. JCard Fail 2011, 17:613-621.
72. Karlstrom P., Alehagen U., Boman K., et al. Brain natriuretic peptide-guided treatment does not improve morbidity and mortality in extensively treated patients with chronic heart failure: responders to treatment have a significantly better outcome. Eur J Heart Fail 2011, 13:1096-1103.
73. Savarese G., Trimarco B., Dellegrottaglie S., et al. Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials. PLoS One 2013, 8:e58287.
74. Boyle A., Sobotka P.A. Redefining the therapeutic objective in decompensated heart failure: hemoconcentration as a surrogate for plasma refill rate. JCard Fail 2006, 12:247-249.
75. Leypoldt J.K., Cheung A.K., Steuer R.R., et al. Determination of circulating blood volume by continuously monitoring hematocrit during hemodialysis. JAm Soc Nephrol 1995, 6:214-219.
76. Davila C., Reyentovich A., Katz S.D. Clinical correlates of hemoconcentration during hospitalization for acute decompensated heart failure. JCard Fail 2011, 17:1018-1022.
77. van der Meer P., Postmus D., Ponikowski P., et al. The predictive value of short-term changes in hemoglobin concentration in patients presenting with acute decompensated heart failure. JAm Coll Cardiol 2013, 61:1973-1981.
78. Oh J., Kang S.M., Hong N., et al. Hemoconcentration is a good prognostic predictor for clinical outcomes in acute heart failure: data from the Korean Heart Failure (KorHF) Registry. Int J Cardiol 2013, 168:4739-4743.
79. Testani J.M., Brisco M.A., Chen J., et al. Timing of hemoconcentration during treatment of acute decompensated heart failure and subsequent survival: importance of sustained decongestion. JAm Coll Cardiol 2013, 62:516-524.
80. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
81. Oliveira-Carvalho V., da Silva M.M., Guimaraes G.V., et al. MicroRNAs: new players in heart failure. Mol Biol Rep 2013, 40:2663-2670.
82. van Rooij E., Marshall W.S., Olson E.N. Toward microRNA-based therapeutics for heart disease: the sense in antisense. Circ Res 2008, 103:919-928.
83. Zhu H., Fan G.C. Extracellular/circulating microRNAs and their potential role in cardiovascular disease. Am J Cardiovasc Dis 2011, 1:138-149.
84. Dickinson B.A., Semus H.M., Montgomery R.L., et al. Plasma microRNAs serve as biomarkers of therapeutic efficacy and disease progression in hypertension-induced heart failure. Eur J Heart Fail 2013, 15:650-659.